Clinical trial · Observational
The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer
NCT01634984CI-TRIAL-00020268unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Selected 400 cases of women with primary breast cancer who were treated with operation randomly, then detect the expression of CDK5RAP2 of cancer tissue. At the same time randomly selected 100 women with primary breast cancer who were under neoadjuvant chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: 1. Provision of informed consent 2. Pathological confirmation of breast cancer 3. Tumor stage(TNM):T2-4bN0-3M0 4. ER(+) and/or PR(+). 5. Premenopausal woman. 6. Age≥40 years 7. Measurable disease as per RECIST criteria 8. Karnofsky≥70 9. Laboratory criteria: * PLT≥100\*109/L * WBC≥4000/mm3 * HGB≥10g/dl * ALT and AST\<2\*ULN Exclusion Criteria: 1. Presence of metastatic disease. 2. Inflammatory breast cancer. 3. Bilateral breast cancer. 4. previous chemotherapy or hormonal therapy for current breast neoplasm. 5. other malignant tumor (concurrent or previous). 6. Pregnant woman. 7. Hypersensitive to any drug in CEF regimen or any ingredient of Zoladex. 8. Any severe systemic disease contraindicating chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.